Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients

被引:149
作者
Ferrandina, G
Lauriola, L
Distefano, MG
Zannoni, GF
Gessi, M
Legge, F
Maggiano, N
Mancuso, S
Capelli, A
Scambia, G
Ranelletti, FO
机构
[1] Univ Cattolica Sacro Cuore, Dept Histol, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dept Obstet & Gynecol, I-00168 Rome, Italy
[3] Univ Cattolica Sacro Cuore, Dept Pathol, I-00168 Rome, Italy
关键词
D O I
10.1200/JCO.20.4.973
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the expression of cyclooxygenase (COX-2) and its association with clinicopathologic parameters and clinical outcome in patients with cervical cancer. Patients and Methods: The study included 84 patients with stage IS to IVA cervical cancer. Patients with early-stage cases (n = 21) underwent radical surgery, whereas patients with locally advanced cervical cancer (LACC) (n = 63) were first administered neoadjuvant cisplatin-based treatment and subjected to surgery in case of response. Immunohistochemical analysis was performed on paraffin-embedded sections with rabbit antiserum against COX-2. Results: COX-2-integrated density values in the overall population ranged from 1.2 to 82.3, with mean +/- SE values of 27.4 +/- 2.4. According to the chosen cutoff value, 36 (42.9%) of 84 patients were scored as COX-2 positive. COX-2 levels were shown to be highly associated with tumor susceptibility to neoadjuvant treatment. COX-2 showed a progressive increase from mean +/- SE values of 19.9 +/- 8.0 in complete responders through 31.5 +/- 3.5 in partial responses to 44.8 +/- 3.9 in patients who were not responsive (P = .0054). When logistic regression was applied, only advanced stage and COX-2 positivity retained independent roles in predicting a poor chance of response to treatment. COX-2-positive patients had a shorter overall survival (OS) rate than COX-2-negative patients. In patients with LACC, the 2-year OS rate was 38% in COX-2-positive versus 85% in COX-2-negative patients (P = .0001). In the muitivariate analysis, only advanced stage and COX-2 positivity retained independent negative prognostic roles for OS. Conclusion: The assessment of COX-2 status could provide additional information to identify patients with cervical cancer with a poor chance of response to neoadjuvant treatment and unfavorable prognosis. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:973 / 981
页数:9
相关论文
共 50 条
[1]  
Achiwa H, 1999, CLIN CANCER RES, V5, P1001
[2]   DANGERS OF USING OPTIMAL CUTPOINTS IN THE EVALUATION OF PROGNOSTIC FACTORS [J].
ALTMAN, DG ;
LAUSEN, B ;
SAUERBREI, W ;
SCHUMACHER, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) :829-835
[3]  
[Anonymous], 1989, Analysis of binary data
[4]   Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer [J].
Benedetti-Panici, P ;
Greggi, S ;
Scambia, G ;
Amoroso, M ;
Salerno, MG ;
Maneschi, F ;
Cutillo, G ;
Paratore, MP ;
Scorpiglione, N ;
Mancuso, S .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (03) :341-346
[5]  
Chao HT, 1999, EUR J GYNAECOL ONCOL, V20, P136
[6]  
Chung EJ, 1999, ACTA ONCOL, V38, P449
[7]  
Cooper RA, 1998, CLIN CANCER RES, V4, P2795
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]  
DeVita VT., 1997, CANC PRINCIPLES PRAC, V5th
[10]   Nonsteroidal antiinflammatory drugs, eicosanoids, and colorectal cancer prevention [J].
DuBois, RN ;
Giardiello, FM ;
Smalley, WE .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1996, 25 (04) :773-+